ライフサイエンスコーパス: serous

1 elial ovarian cancers were identified (3,378 serous, 606 endometrioid, 331 mucinous, 269 clear cell,

2 ssociation between GSN expression in ovarian serous adenocarcinoma and progression free survival and

3 rowth of three of five lethal chemoresistant serous adenocarcinoma PDXa models without signs of measu

4 rade serous, four serous-type, one low-grade serous and 20 non-serous type.

5 hat they occurred more commonly in eyes with serous and drusenoid PED.

6 rian cancer, including clear cell, low-grade serous and endometrioid carcinomas.

7 low-grade serous carcinomas from high-grade serous and mucinous carcinomas.

8 lts highlight mutational differences between serous and non-serous ovarian cancers, and further disti

9 to upregulate the EGFR pathway in high-grade serous and other ovarian cancer cells.

10 Five serous and/or serous-like (serous/serous-like) endometri

11 ith both nonvascularized PEDs (drusenoid and serous) and vascularized PEDs (type 1 and type 3 neovasc

12 expression of IRF6 in the developing ductal, serous, and mucous acinar cells of salivary glands.

13 BRAF and KRAS mutations are common in serous borderline (SB) and LGS ovarian cancers, and MEK

14 Dissimilarly, serous borderline ovarian tumors (BOT) can progress into

15 visualization of fine papillary branches in serous BOT and allowed for characterization of spatial f

16 emonstrate challenges for risk prediction of serous cancers, the most fatal subtype.

17 loss is a hallmark of the earliest stages of serous carcinogenesis and occurs both at the DNA, RNA an

18 molecular aberration in the FTE occurring in serous carcinogenesis followed by a mutation in p53.

19 valuated the functional role of cyclin E1 in serous carcinogenesis.

20 r cell carcinoma (Arid1a, Pik3ca), low-grade serous carcinoma (Braf), endometrioid (Ctnnb1), or mucin

21 High-grade serous carcinoma (HGSC) is the most prevalent and lethal

22 g evidence indicates that ovarian high-grade serous carcinoma (HGSC) originates from fallopian tube s

23 lantable murine models of ovarian high grade serous carcinoma (HGSC) remain an important research too

24 Ovarian high-grade serous carcinoma (HGSC) results in the highest mortality

25 lantable murine models of ovarian high-grade serous carcinoma (HGSC) with regard to mutations in the

26 cantly increased risk for ovarian high-grade serous carcinoma (HGSC; 3.8% cases vs. 0.2% controls).

27 g squamous cell carcinoma (LSCC) and ovarian serous carcinoma (OSC).

28 Women age < 35 years with low-grade serous carcinoma and those with persistent disease at co

29 ate that the precursor of ovarian high-grade serous carcinoma appears to develop from an occult intra

30 Low-grade serous carcinoma of the ovary (LGSOC) or peritoneum (LGS

31 erapy in women with stage II to IV low-grade serous carcinoma of the ovary or peritoneum.

32 a deep analysis of one patient with advanced serous carcinoma of the ovary.

33 ation of chemotherapy in ovarian and uterine serous carcinoma patients by biodegradable nanoparticles

34 among patients with stage II to IV low-grade serous carcinoma treated with primary surgery followed b

35 nclusion Women with stage II to IV low-grade serous carcinoma who received HMT after primary treatmen

36 common subtype of ovarian cancer, high-grade serous carcinoma, has sparked a major effort within the

37 Uterine serous carcinoma, one of the most aggressive types of en

38 High-grade serous carcinoma, which often arises from the fallopian

39 against i.p. chemotherapy-resistant uterine serous carcinoma-derived xenografts compared with free E

40 shows prognostic significance for high-grade serous carcinoma.

41 rotransposition events in high-grade ovarian serous carcinoma.

42 al fallopian tube among all cases.High-grade serous carcinomas (HGSCs) are associated with precursor

43 Many high-grade serous carcinomas (HGSCs) of the pelvis are thought to o

44 e Atlas (TCGA), of which 169 were high-grade serous carcinomas (HGSCs).

45 ian tumors (BOT) can progress into low-grade serous carcinomas and have relatively indolent clinical

46 Because serous carcinomas are the most common EOC and account fo

47 en observed at high frequency in endometrial serous carcinomas but at low frequency in ovarian clear

48 ated endometrioid, clear cell, and low-grade serous carcinomas from high-grade serous and mucinous ca

49 Endometrioid and low-grade serous carcinomas had similar correlation coefficients (

50 cular pathogenesis of fallopian tube-derived serous carcinomas is poorly understood and there are few

51 n tube are putative precursors to high-grade serous carcinomas of the ovary and peritoneum.

52 e composed, for the most part, of high-grade serous carcinomas that can be further subdivided into mo

53 l cancers collectively referred to as pelvic serous carcinomas, is not well known.

54 hways through profiling of normal FTSECs and serous carcinomas.

55 , and seromucinous carcinomas; ii) low-grade serous carcinomas; and iii) mucinous carcinomas and mali

56 d innate-like B-cell immune responses in the serous cavities.

57 atelike lymphocytes that primarily reside in serous cavities.

58 in a subset of mononuclear leukocytes and in serous cells of submucosal glands.

59 For DME (140 scans) and central serous chorioretinopathy (91 scans), 25-line raster conf

60 Chronic central serous chorioretinopathy (cCSC) is a chorioretinal disea

61 association in patients with chronic central serous chorioretinopathy (cCSC).

62 Central Serous Chorioretinopathy (CSC) has been previously repor

63 (EDI) and swept-source (SS) OCT, in central serous chorioretinopathy (CSC).

64 ajor cause of vision loss in chronic central serous chorioretinopathy (CSCR).

65 ith choroidal neovascularization and central serous chorioretinopathy (CSCR).

66 to a fifth of patients with chronic central serous chorioretinopathy but carry a relatively good vis

67 three eyes of 30 patients with acute central serous chorioretinopathy comprised the comparative group

68 eyes; severe cough in 1.9% of eyes; central serous chorioretinopathy in 1.4% of eyes; intraocular le

69 Patients with classic CNV and central serous chorioretinopathy were excluded.

70 Consecutive patients with chronic central serous chorioretinopathy were identified from the clinic

71 Sixty-seven patients with chronic central serous chorioretinopathy were identified.

72 preceding 2 years, had a history of central serous chorioretinopathy, and did not have a history of

73 tion of fluid is a common finding in central serous chorioretinopathy, but it has a different pattern

74 tecting fluid in DME, BRVO/CRVO, and central serous chorioretinopathy, but not neovascular AMD.

75 oroidal vascular changes, similar to central serous chorioretinopathy, but specifically confined in t

76 pairment of the photoreceptor layer (central serous chorioretinopathy, chronic central serous chorior

77 al serous chorioretinopathy, chronic central serous chorioretinopathy, maculopathy associated with hy

78 retinal vein occlusion (CRVO/BRVO), central serous chorioretinopathy, vitreomacular traction, and fu

79 utive cohort of patients, with acute central serous chorioretinopathy, was also examined for the pres

80 st that they are specific to chronic central serous chorioretinopathy.

81 Seven eyes had CNV associated with central serous chorioretinopathy.

82 e distinguished from the findings of central serous chorioretinopathy.

83 ors and compared our results to TCGA ovarian serous cystadenocarcinoma and uterine corpus endometrial

84 project: glioblastoma multiforme and ovarian serous cystadenocarcinoma.

85 patients with IPMN, but not in patients with serous cystadenoma or controls.

86 cysts, and two of four neoplasms (50%) (all serous cystadenomas) demonstrated T2 dark spots.

87 should be distinguished from serous lesions (serous cystadenomas) that are nearly always benign.

88 Although many cysts, such as pseudocysts and serous cystadenomas, are benign and can be monitored cli

89 cinous neoplasms, mucinous cystic neoplasms, serous cystadenomas, solid pseudopapillary neoplasms, cy

90 f vision, presence of subretinal hemorrhage, serous detachment, retinal pigment epithelial detachment

91 oveal severe exudation with a posterior pole serous detachment.

92 characterized by schisis-like thickening and serous detachment.

93 tures of AEPVM, including initial localized, serous detachments followed by the development of charac

94 ially relapsed platinum-sensitive high-grade serous disease.

95 A2 mutation prevalence was 11% in high-grade serous disease.

96 ignaling, illuminating the genetic basis for serous EC development and its potential control by ratio

97 r light chain deposition disease may develop serous elevations of the macula that we classify as acqu

98 genomic alterations that occur frequently in serous endometrial carcinoma (EC) and carcinosarcoma, tw

99 e compared as were the carcinoma histotypes (serous, endometrioid, clear cell).

100 Specifically, 8% of high-grade serous EOC from The Cancer Genome Atlas dataset exhibite

101 At least 1 in 10 women with high-grade serous EOC has a BRCA1 or BRCA2 mutation.

102 y loci for different EOC histotypes: six for serous EOC histotypes (3q28, 4q32.3, 8q21.11, 10q24.33,

103 riants were specifically associated with the serous EOC subtype, all with P < 5 x 10(-8).

104 Kras(G12D)-mutant mouse strain that develops serous EOC with 100% penetrance to introduce the mutant

105 eptibility gene for low-grade and borderline serous EOC.

106 HRD phenotype was most common in high grade serous EOC.

107 tations in non-serous was much lower than in serous epithelial OC, whereas the prevalence of PIK3CA,

108 ted 11 regions conferring risk of high-grade serous epithelial ovarian cancer (HGSOC).

109 dies have revealed the mutation landscape of serous epithelial ovarian cancer, other non-serous subty

110 Here we conduct exome sequencing of nine non-serous epithelial ovarian tumors (six endometrioid and t

111 te a 30-40-fold increased risk of high-grade serous extra-uterine Mullerian cancers (HGSEMC), otherwi

112 s from the glycoproteins common to serum and serous fluid.

113 r cell lines, 14 were assigned as high-grade serous, four serous-type, one low-grade serous and 20 no

114 n any gene were more likely to be high grade serous, have an earlier diagnosis age and have ovarian a

115 ms underlying clinical outcome of high-grade serous (HGS) epithelial ovarian carcinomas (EOC), we eva

116 High-grade serous (HGS) ovarian cancer accounts for 90% of all ovar

117 d the prognostic value of CD73 in high-grade serous (HGS) ovarian cancer using gene and protein expre

118 opean descent, including 6,179 of high-grade serous (HGS), 2,100 endometrioid, 1,591 mucinous, 1,034

119 rer survival included: clear/mucinous versus serous histology (AHR, 2.79; 95% CI, 1.83 to 4.24; P < .

120 Serous histology was the best predictor of lack of respo

121 inous, 1,034 clear cell, and 1,016 low-grade serous, including 23,235 control cases spanning 40 studi

122 iation for flavanone intake was stronger for serous invasive and poorly differentiated tumors (compar

123 t potential and should be distinguished from serous lesions (serous cystadenomas) that are nearly alw

124 xists for patients with metastatic low-grade serous (LGS) ovarian cancers.

125 Five serous and/or serous-like (serous/serous-like) endometrial carcinomas

126 e agents have been associated with a central serous-like retinopathy in some patients.

127 l sutureless pars plana vitrectomy (PPV) for serous macular detachment associated with optic disc pit

128 mopathy-producing pathologic antibodies with serous macular detachment being an uncommon ocular manif

129 safe and effective method for management of serous macular detachment resulting from optic disc pits

130 coherence tomography (OCT) documentation of serous macular detachment were reviewed.

131 er retinal schisis; 2 of them had associated serous macular detachment while inner retinal schisis wa

132 To test this novel therapeutic peptide, serous malignant ascites from highly resistant recurrent

133 year, the therapy was started again and the serous neuroretinal detachment appeared once more, howev

134 Fundoscopy showed serous neuroretinal detachment of the fovea accompanied

135 ify 13 candidate causal SNPs associated with serous OC (P=9.2 x 10(-20)), ER-negative BC (P=1.1 x 10(

136 tumors, ORlog2 = 1.40 (1.03-1.91)], but not serous or clear cell.

137 with recurrent platinum-sensitive high-grade serous or endometrioid ovarian cancer, and warrants stud

138 ble platinum-sensitive, relapsed, high-grade serous or endometrioid ovarian, fallopian tube, or prima

139 older, had a platinum-sensitive, high-grade serous or endometrioid ovarian, primary peritoneal, or f

140 loiting the sidedness of BP scaffolds (i.e., serous or fibrous surface), this study aims to determine

141 hological characteristics (eg, endometrioid, serous, or clear-cell adenocarcinoma).

142 sorder, receptive language disorder, chronic serous otitis media, and expressive language disorder.

143 n important role in the growth of high-grade serous ovarian (HGS-OvCa) and other cancers, but its cli

144 algorithms and used them with 296 high-grade serous ovarian (HGS-OvCa) tumor and 1,839 normal RNA-seq

145 alignancy in the United States, and advanced serous ovarian adenocarcinoma is responsible for most ov

146 Disseminated high-grade serous ovarian cancer (HGS-OvCa) is an aggressive diseas

147 In models of high-grade serous ovarian cancer (HGS-OVCa), CDK12 attenuation was

148 BRCA2 mutations in patients with high-grade serous ovarian cancer (HGSC) are associated with favorab

149 Patients with high-grade serous ovarian cancer (HGSC) have experienced little imp

150 High-grade serous ovarian cancer (HGSC) is among the most lethal fo

151 High-grade serous ovarian cancer (HGSC) is an aggressive cancer wit

152 of the progenitor populations for high-grade serous ovarian cancer (HGSC).

153 recognized as a site of origin of high-grade serous ovarian cancer (HGSC).

154 mor tissue from 158 patients with high-grade serous ovarian cancer (HGSOC) and 100 control patients w

155 ted tomography (CT) phenotypes of high-grade serous ovarian cancer (HGSOC) and to evaluate CT indicat

156 cal challenge in the treatment of high-grade serous ovarian cancer (HGSOC) is the development of prog

157 repressed in approximately 30% of high-grade serous ovarian cancer (HGSOC) patients and is a recurren

158 cell line representative of human high-grade serous ovarian cancer (HGSOC) should not only resemble i

159 mography (CT) imaging features of high-grade serous ovarian cancer (HGSOC), to assess their associati

160 etermine early somatic changes in high-grade serous ovarian cancer (HGSOC), we performed whole genome

161 proved biomarkers for olaparib in high-grade serous ovarian cancer (HGSOC).

162 oups, especially in patients with high-grade serous ovarian cancer (HGSOC).

163 uded 244 patients with pathologically proven serous ovarian cancer (mean age +/- standard deviation,

164 In high-grade serous ovarian cancer (OV), the bulk of genetic changes

165 cedes the radiologic detection of high-grade serous ovarian cancer by at least 2 mo and the final cli

166 r cell line (OVCAR8) and a subset of primary serous ovarian cancer cell strains (DFs).

167 In the serous ovarian cancer cells (IGROV and OVCAR-3), shPKCio

168 bine sensitivity in low-grade and high-grade serous ovarian cancer cells.

169 est DESI-MS as a powerful approach for rapid serous ovarian cancer diagnosis based on altered metabol

170 High-grade serous ovarian cancer is an aggressive form of epithelia

171 High-grade serous ovarian cancer is the most common ovarian cancer

172 stologically confirmed, relapsed, high-grade serous ovarian cancer or high-grade endometrioid cancer,

173 In matched samples from 11 high-grade serous ovarian cancer patients, we detected 2-20-fold mo

174 metastases, and ascites cells isolated from serous ovarian cancer patients.

175 th BRCA-mutated platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance mon

176 etic testing to all patients with high-grade serous ovarian cancer regardless of family history.

177 We performed an analysis of CNV data of 587 serous ovarian cancer samples on multiple platforms.

178 line and as small as 9 Mb in two high-grade serous ovarian cancer samples using only 0.02x depth.

179 d multi-omics profiles of primary high-grade serous ovarian cancer tumours (N=357) to delineate mecha

180 romal gene signature for advanced high-grade serous ovarian cancer using microdissected stromal ovari

181 l siRNA delivery system and a mouse model of serous ovarian cancer were used to test predictions from

182 , patients with platinum-sensitive recurrent serous ovarian cancer who had received two or more cours

183 n patients with platinum-sensitive recurrent serous ovarian cancer who had received two or more plati

184 th platinum-sensitive, recurrent, high-grade serous ovarian cancer who had received up to three previ

185 t patients with platinum-sensitive recurrent serous ovarian cancer with a BRCA mutation have the grea

186 th platinum-sensitive, recurrent, high-grade serous ovarian cancer with or without BRCA1 or BRCA2 mut

187 meta-analysis on the results for high-grade serous ovarian cancer with the results from analysis of

188 ) (CaMKK2) is highly expressed in high-grade serous ovarian cancer, and we investigated its role in A

189 n patients with platinum-sensitive recurrent serous ovarian cancer, including those with BRCA1 and BR

190 n patients with platinum-sensitive recurrent serous ovarian cancer, maintenance monotherapy with the

191 xceptional case of a patient with high-grade serous ovarian cancer, treated with multiple chemotherap

192 aluated as a diagnostic probe for high-grade serous ovarian cancer, typically diagnosed at late stage

193 development of drug resistance in high-grade serous ovarian cancer, were examined from patient derive

194 th BRCA-mutated platinum-sensitive recurrent serous ovarian cancer.

195 nning and treatment monitoring of high-grade serous ovarian cancer.

196 overall survival in patients with high-grade serous ovarian cancer.

197 with platinum-sensitive, relapsed high-grade serous ovarian cancer.

198 for testing in patients with chemoresistant serous ovarian cancer.

199 th platinum-sensitive, recurrent, high-grade serous ovarian cancer.

200 he TGF-beta signalling pathway in high-grade serous ovarian cancer.

201 n patients with platinum-sensitive recurrent serous ovarian cancer.

202 m patients with high grade but not low grade serous ovarian cancer.

203 ortance of metastatic hepatic involvement in serous ovarian cancer.

204 ely monitor the progression and treatment of serous ovarian cancer.

205 erformed phylogenetic analysis of high-grade serous ovarian cancers (68 samples from seven patients),

206 ance in ovarian and other cancers.High-grade serous ovarian cancers (HGS-OvCa) frequently develop che

207 k of effective chemotherapies for high-grade serous ovarian cancers (HGS-OvCa) has motivated a search

208 High-grade serous ovarian cancers (HGSCs) are deadly malignancies t

209 , the debated cellular origins of high-grade serous ovarian cancers (HGSOCs) and in endometriosis epi

210 rexpressed in a subset of primary high-grade serous ovarian cancers and cell lines.

211 amplified with PIK3CA in 29.3% of high-grade serous ovarian cancers and its overexpression is signifi

212 High-grade serous ovarian cancers are characterized by widespread r

213 CAPRO underestimated the risk for high-grade serous ovarian cancers but overestimated the risk for ot

214 utational differences between serous and non-serous ovarian cancers, and further distinguish differen

215 ver clonal populations comprising high-grade serous ovarian cancers.

216 ir, occur in approximately 20% of high grade serous ovarian cancers.

217 High-grade serous ovarian carcinoma (HGSOC) and basal-like breast c

218 A key feature of high-grade serous ovarian carcinoma (HGSOC) is frequent amplificati

219 High-grade serous ovarian carcinoma (HGSOC) is the most common and

220 High-grade serous ovarian carcinoma (HGSOC) is the most frequent ty

221 High-grade serous ovarian carcinoma (HGSOC), the most lethal gyneco

222 tations are a defining feature of high-grade serous ovarian carcinoma (HGSOC).

223 Serous ovarian carcinoma is the most lethal gynecologica

224 s a candidate oncogenic driver in high-grade serous ovarian carcinoma, we evaluated the functional ro

225 CDK12 is a recurrently mutated gene in serous ovarian carcinoma, whose downregulation is associ

226 erived and in-house cohorts of patients with serous ovarian carcinoma.

227 ted with CDK12 inactivation in patients with serous ovarian carcinoma.

228 ession predicts poor prognosis in high-grade serous ovarian carcinoma.

229 d the dominant site of origin for high-grade serous ovarian carcinoma.

230 nes and in organoids derived from high-grade serous ovarian carcinomas (HGSOC), an aggressive cancer

231 peritoneal fluid from women with high-grade serous ovarian carcinomas (HGSOCs).

232 Low-grade serous ovarian carcinomas (LGSC) are associated with a p

233 aberrations to those observed in high-grade serous ovarian carcinomas suggests that genetic biomarke

234 ls that are the site of origin of high-grade serous ovarian carcinomas.

235 T80/KLF8 tumors were characteristic of human serous ovarian carcinomas.

236 ian tube carcinomas compared with high-grade serous ovarian carcinomas.

237 ctor FOXO3a in a vast majority of high-grade serous ovarian carcinomas.

238 rotein levels were upregulated in high-grade serous ovarian patient tumors, where the FoxM1 signature

239 involvement in cancer from additional 28 non-serous ovarian tumors and compared our results to TCGA o

240 eceptor expression in a tissue microarray of serous ovarian tumors by immunohistochemistry and found

241 Many cancers, however, including high-grade serous ovarian, oesophageal, and small-cell lung cancer,

242 on pathways associated with chemoresponse in serous OVCA in three independent gene-expression experim

243 g The Cancer Genome Atlas (TCGA) dataset for serous OVCA.

244 er PED at baseline (P = .001), predominantly serous PED (P = .003), and the use of aflibercept (P = .

245 The volume of the migrated RPE cluster in serous PED was significantly correlated with the volume

246 noid pigment epithelial detachment (PED) and serous PED with significantly higher frequencies than in

247 k choroid and predominantly nonvascularized, serous PEDs with an overlying neurosensory detachment.

248 l window of opportunity to detect high-grade serous peritoneal carcinoma arising from the fallopian t

249 ented with nystagmus and was found to have a serous RD and a tessellated retinal appearance.

250 All eyes presented a fluctuating course of serous RD during follow-up.

251 Eyes with serous RD had thicker choroid (P = .004) and tended to h

252 Serous RD in dome-shaped macula was likely caused by cho

253 Worsening of serous RD was associated with appearance of new punctate

254 Serous RD was not associated with hyperpermeability area

255 Serous RD was the most common abnormality associated wit

256 the staphyloma between eyes with and without serous RD.

257 We also measured serous retinal detachment (SRD) only with SS-OCT.

258 Main outcome measures included resolution of serous retinal detachment (SRD) with single PDT, change

259 choroidal lesions, complicated by recurrent serous retinal detachment (SRD).

260 All 26 eyes with a serous retinal detachment at baseline resolved, and 88%

261 loped bilateral anterior uveitis and macular serous retinal detachment during nivolumab treatment for

262 Serous retinal detachment has been described as a rare c

263 apilledema and macular edema associated with serous retinal detachment in the left eye.

264 ral anterior uveitis associated with macular serous retinal detachment related to anti-PD-1 treatment

265 Serous retinal detachment showed fluctuating changes ove

266 Serous retinal detachment was confirmed on optical coher

267 inner layer separation improved before than serous retinal detachment.

268 omography, dilation of choroidal vessels and serous retinal detachments (SRDs) were observed and conf

269 their metastatic cancer, who had evidence of serous retinal detachments confirmed by optical coherenc

270 One patient (2 eyes) had diffuse serous retinal detachments involving not only the macula

271 an Eye and Ear Hospital with acute bilateral serous retinal detachments without anterior chamber infl

272 clinical and morphologic characteristics of serous retinal disturbances in patients taking mitogen-a

273 ystic changes, choroidal neovascularization, serous retinal elevations mimicking retinal folds, incre

274 A time-dependent and reversible serous retinopathy can develop both in patients with met

275 A cause of binimetinib-associated serous retinopathy may be toxicity of medication, but au

276 Bilateral central serous retinopathy-like events have been described in pa

277 and/or protein expression in all 3 available serous/serous-like BRCA1+ tumors.

278 r after RRSO was not increased, the risk for serous/serous-like endometrial carcinoma was increased i

279 Five serous and/or serous-like (serous/serous-like) endometrial carcinomas were observed

280 Additionally, serous side seeding significantly increased hMSC adhesio

281 Basement membrane structures on the serous side stimulated hMSC cell monolayer formation, wh

282 etion occurs predominantly in poor prognosis serous subtype tumours, and this genetic deletion is ass

283 serous epithelial ovarian cancer, other non-serous subtypes of the disease have not been explored as

284 ncers, and further distinguish different non-serous subtypes.

285 pGs accurately discriminate HGSEMCs from non-serous subtypes.

286 Serous tubal intra-epithelial carcinoma (STIC) lesions a

287 ssed in early fallopian tube lesions, called serous tubal intraepithelial carcinoma.

288 cted fallopian tube lesions (p53 signatures, serous tubal intraepithelial carcinomas (STICs), and fal

289 veloping from small precursor lesions called serous tubal intraepithelial carcinomas (TICs, or more s

290 nonsignificantly increased risk of low-grade serous tumors (pOR = 1.48, 95% CI: 0.92, 2.38) was noted

291 erved between androstenedione and high grade serous tumors [ORlog2 = 0.76 (0.60-0.96)].

292 -grade primary tumor patients with papillary serous tumors of the ovary.

293 tumors (3), low grade (4) and high grade (5) serous tumors, and endometrioid tumors (6).

294 iltrating lymphocytes (TILs) from high-grade serous tumors, defined their suppressive capacity in vit

295 nt loss of PAX2 in benign lesions as well as serous tumors.

296 serous-type, one low-grade serous and 20 non-serous type.

297 ephritis are not vascularized, but rather of serous type.

298 14 were assigned as high-grade serous, four serous-type, one low-grade serous and 20 non-serous type

299 FBXW7, and KRAS, similar to endometrioid and serous uterine carcinomas.

300 Prevalence of TP53 mutations in non-serous was much lower than in serous epithelial OC, wher